FILE - This undated file photo provided by Schering-Plough shows the cholesterol-lowering drug Vytorin, the product of a joint venture between pharmaceutical companies Merck & Co., and Schering-Plough Corp. Merck & Co. announced Thursday, Feb. 14, 2013, it has agreed to pay $688 million to settle two long-running lawsuits brought by investors who alleged the drugmaker delayed releasing bad news on its blockbuster cholesterol drugs to prevent a drop in sales. (AP Photo/Schering-Plough Corp., File)

Associated Press
FILE - This undated file photo provided by Schering-Plough shows the cholesterol-lowering drug Vytorin, the product of a joint venture between pharmaceutical companies Merck & Co., and Schering-Plough Corp. Merck & Co. announced Thursday, Feb. 14, 2013, it has agreed to pay $688 million to settle two long-running lawsuits brought by investors who alleged the drugmaker delayed releasing bad news on its blockbuster cholesterol drugs to prevent a drop in sales.  (AP Photo/Schering-Plough Corp., File)
FILE - This undated file photo provided by Schering-Plough shows the cholesterol-lowering drug Vytorin, the product of a joint venture between pharmaceutical companies Merck & Co., and Schering-Plough Corp. Merck & Co. announced Thursday, Feb. 14, 2013, it has agreed to pay $688 million to settle two long-running lawsuits brought by investors who alleged the drugmaker delayed releasing bad news on its blockbuster cholesterol drugs to prevent a drop in sales. (AP Photo/Schering-Plough Corp., File)
View Comments (0)